An insight into potential of nanoparticles-assisted chemotherapy of cancer using gemcitabine and its fatty acid prodrug: A comparative study

Journal of Biomedical Nanotechnology

Volumn 9, Issue 5, 2013, Pages 915-925

  Gupta, A ^a   Asthana, S ^a   Konwar, R ^a   Chourasia, M K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Cytotoxicity; Nucleoside Analogue; Poly Lactic Co Glycolic Acid; Stearic Acid; Stearoyl Gemcitabine

Indexed keywords

CLINICAL OUTCOME; COMPARATIVE STUDIES; FATTY ACID DERIVATIVES; FLOW-CYTOMETRIC ANALYSIS; NUCLEOSIDE ANALOGUES; POLY LACTIC-CO-GLYCOLIC ACID; STEAROYL-GEMCITABINE; SUSTAINED DRUG RELEASE;

CHEMOTHERAPY; CYTOTOXICITY; DISEASES; FATTY ACIDS; NANOPARTICLES; STEARIC ACID; SYNTHESIS (CHEMICAL); TISSUE;

DRUG PRODUCTS;

FATTY ACID; GEMCITABINE; NANOPARTICLE; POLYGLACTIN; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG RELEASE; ENCAPSULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PARTICLE SIZE; ZETA POTENTIAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; FATTY ACIDS; FEMALE; HUMANS; MALE; MICE; NANOPARTICLES; NEOPLASMS; PRODRUGS; RATS; RATS, WISTAR;

EID: 84877748856     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1591     Document Type: Article

References (30)

1. W. Plunkett, P. Huang, and V. Gandhi, Preclinical characteristics of gemcitabine. Anticancer Drugs 6, 7 (1995).
2. A. M. Bergman, A. D. Adema, J. Balzarini, S. Bruheim, I. Fichtner, P. Noordhuis, O. Fodstad, F. Myhren, M. L. Sandvold, H. R. Hendriks, and G. J. Peters, Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invst. New Drugs 29, 456 (2011).
3. M. L. Immordino, P. Brusa, F. Rocco, S. Arpicco, M. Ceruti, and L. Cattel, Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J. Controlled Rel. 100, 331 (2004).
4. L. H. Reddy and P. Couvreur, Novel approaches to deliver gemcitabine to cancers. Curr. Pharm. Res. 14, 1124 (2008).
5. M. Pastor-Anglada, M. Molina-Arcas, F. J. Casado, B. Bellosillo, D. Colomer, and J. Gil, Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 18, 385 (2004).
6. C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 68, 1970 (2008).
7. J. L. Arias, L. H. Reddy, and P. Couvreur, Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J. Drug Target 17, 586 (2009).
8. M. Vandana and S. K. Saho, Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials 31, 9340 (2010).
9. 4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model. J. Drug Target 15, 445 (2007).
10. L. H. Reddy, C. Dubernet, S. L. Mouelhi, P. E. Marque, D. Desmaele, and P. Couvreur, A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J. Controlled Rel. 124, 20 (2007).
11. Y. H. Jiao, Y. Li, S. Wang, K. Zhang, Y. G. Jia, and Y. Fu, Layerby- layer assembly of poly(lactic acid) nanoparticles: A facile way to fabricate films for model drug delivery. Langmuir 26, 8270 (2010).
12. R. S. Mulik, J. Monkkonen, R. O. Juvonen, K. R. Mahadik, and A. R. Paradkar, ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: Study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol. Pharm. 7, 815 (2010).
13. J. Panyam and V. Labhasetwar, Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Del. Rev. 55, 329 (2003).
14. J. S. Chawla and M. M. Amiji, Biodegradable poly(epsiloncaprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int. J. Pharm. 249, 127 (2002).
15. W. Zou, C. Liu, Z. Chen, and N. Zhang, Studies on bioadhesive PLGA nanoparticles: A promising gene delivery system for efficient gene therapy to lung cancer. Int. J. Pharm. 370, 187 (2009).
16. D. Konerding, T. L. James, E. Trump, A. M. Soto, L. A. Marky, and W. H. Gmeiner, NMR structure of a gemcitabine-substituted model Okazaki fragment. Biochemistry 41, 839 (2002).
17. E. Cohen-Sela, M. Chorny, N. Koroukhov, H. D. Danenberg, and G. Golomb, A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J. Controlled Rel. 133, 90 (2009).
18. T. Garg, S. Jain, H. P. Singh, A. Sharma, and A. K. Tiwary, Elastic liposomal formulation for sustained delivery of antimigraine drug: In vitro characterization and biological evaluation. Drug Dev. Ind. Pharm. 34, 1100 (2008).
19. P. W. S. Heng, L. W. Chan, M. G. Easterbrook, and X. Li, Investigation of the influence of mean HPMC particle size and number of polymer particles on the release of aspirin from swellable hydrophilic matrix tablets. J. Controlled Rel. 76, 39 (2001).
20. L. Ostacolo, M. Marra, F. Ungaro, S. Zappavigna, G. Maglio, F. Quaglia, A. Abbruzzese, and M. Caraglia, In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role. J. Controlled Rel. 148, 255 (2010).
21. M. Botta, S. Armaroli, D. Castagnolo, G. Fontana, P. Pera, and E. Bombardelli, Synthesis and biological evaluation of new taxoids derived from 2-deacetoxytaxinine. J. Bioorg. Med. Chem. Letters 17, 1579 (2007).
22. Y. Tokunaga, T. Iwasa, J. Fujisaki, S. Sawai, and A. Kagayama, Liposomal sustained-release delivery systems for intravenous injection II. Design of liposome carriers and blood disposition of lipophilic mitomycin C prodrug-bearing liposomes. Chem. Pharm. Bull. 36, 3557 (1998).
23. P. D. Scholes, A. G. A. Coombes, L. Illum, S. S. Davis, M. Vert, and M.C. Davies, The preparation of Sub-200 Nm poly(lactide-coglycolide) microspheres for site-specific drug delivery. J. Controlled Rel. 25, 145 (1993).
24. A. Carrio, G. Schwach, J. Coudane, and M. Vert, Preparation and degradation of surfactant-free plaga microspheres. J. Controlled Rel. 37, 113 (1995).
25. S. Sugrue, Predicting and controlling colloid suspension stability using electrophoretic mobility and particle-size measurements. Am. Lab. 24, 64 (1992).
26. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Controlled Rel. 65, 271 (2000).
27. P. Brusa, M. L. Immordino, F. Rocco, and L. Cattel, Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. Anticancer Res. 27, 195 (2007).
28. I. Rattmann, V. Kleff, U. R. Sorg, W. Bardenheuer, A. Brueckner, R. A. Hilger, B. Opalka, S. Seeber, M. Flasshove, and T. Moritz, Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model. Blood 108, 2965 (2006).
29. Q. Tian, C. N. Zhang, X. H. Wang, W. Wang, W. Huang, R. T. Cha, C. H. Wang, Z. Yuan, M. Liu, H. Y. Wan, and H. Tang, Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials 31, 4748 (2010).
30. C. Mohanty and S. K. Sahoo, The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 31, 6597 (2010).